Best peptides for gut health
Peptides that support gut lining repair, reduce intestinal inflammation, and improve digestive function.
What to know
BPC-157 is the standout peptide for gut health — originally isolated from gastric juice, it has extensive animal data showing gut lining repair, anti-inflammatory effects, and protection against NSAID-induced damage. Oral BPC-157 may be most effective for gut-specific issues. Larazotide targets tight junction integrity (relevant for celiac and leaky gut). LL-37 has antimicrobial properties. Most gut peptide protocols run 4-8 weeks.
Recommended peptides
BPC-157
healing-recovery
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids derived from a protective protein found naturally in human gastric juice. First isolated and characterized by researcher Predrag Sikiric and his team at the University of Zagreb in the early 1990s, BPC-157 has become one of the most extensively studied peptides in preclinical research, with over 100 published studies investigating its effects across multiple organ systems. The compound earned the nickname "the Wolverine peptide" in biohacking communities due to the breadth of tissue repair observed in animal studies. Research spanning more than three decades has documented effects on tendons, ligaments, muscles, bones, skin, corneas, the gastrointestinal tract, liver, and nervous system in preclinical models. A 2025 systematic review published in HSS Journal (PMID: 40756949) analyzed 36 studies conducted between 1993 and 2024, finding that BPC-157 consistently improved outcomes across musculoskeletal injury models. Despite this extensive preclinical evidence, human clinical data remains extremely limited. As of March 2026, only three small human studies have been published: a 2-person intravenous safety pilot (PMID: 40131143), a small retrospective knee pain study, and a 12-patient interstitial cystitis pilot. The knee pain study reported significant relief in most participants at 6-12 months, and the cystitis pilot reported substantial symptom improvement. Neither of these smaller studies has been published with full peer-reviewed PMIDs. A Phase I safety trial (NCT02637284) was registered by PharmaCotherapia but the sponsor never published results, raising transparency concerns in the research community. BPC-157 is classified as a research compound and is not FDA-approved for any human use. In 2023, the FDA placed BPC-157 in Category 2 of its list of bulk drug substances under evaluation for compounding, meaning it does not meet safety criteria for pharmacy compounding. The World Anti-Doping Agency (WADA) added BPC-157 to its prohibited substances list in 2022 under the S0 category (non-approved substances). Despite these regulatory designations, BPC-157 continues to be widely discussed in peptide research communities and functional medicine circles. The compound is available in injectable and oral forms. Most preclinical research has used subcutaneous or intraperitoneal injection, though studies have also demonstrated activity when administered orally, particularly for gastrointestinal conditions. An important distinction exists between the acetate salt and arginate salt forms. The arginate form reportedly demonstrates significantly better oral bioavailability and stability, though head-to-head bioavailability studies have not been published in peer-reviewed journals. A comprehensive preclinical safety evaluation published in Regulatory Toxicology and Pharmacology (PMID: 32334036) tested BPC-157 across multiple species including mice, rats, rabbits, and dogs. The study found no test-related adverse effects in single-dose or repeated-dose toxicity evaluations, no genetic toxicity, and no embryo-fetal toxicity at doses up to 20 mg/kg over six weeks. However, the absence of large-scale human safety trials means that the long-term safety profile in humans remains unknown. The primary mechanisms through which BPC-157 appears to exert its effects involve the promotion of angiogenesis, modulation of nitric oxide synthesis through multiple pathways, upregulation of growth factor receptors, and interaction with the dopamine and serotonin neurotransmitter systems. These mechanisms have been documented across dozens of studies spanning multiple research groups. BPC-157 occupies a unique position in the peptide landscape. Its broad preclinical evidence base across tissue types, combined with the near-total absence of human clinical trials, creates a significant gap between what animal research suggests and what has been demonstrated in people. All information on this page reflects published research and is presented for educational purposes only.
LL-37
healing-recovery
LL-37 is a human antimicrobial peptide (cathelicidin) that plays a key role in innate immune defense against bacteria, viruses, and fungi.
Get the Gut Health cheat sheet
Dosing quick-reference, key studies, and side effect management — in your inbox.
Recommended stacks
GLP-1 Weight Loss Stack
beginner — $200-600 (compounded) or $1,000+ (brand)
The foundational weight loss protocol using GLP-1 receptor agonists with muscle preservation support. The most evidence-backed approach to significant weight loss.
Gut Restoration Stack
beginner — $80-160
Targeted gut healing protocol for leaky gut, IBS, GERD, or post-antibiotic gut repair using oral and injectable peptides.
The Gut Healing Stack
beginner — $100-200
Targeted gut repair protocol combining BPC-157's mucosal healing with KPV's anti-inflammatory action. BPC-157 rebuilds the gut lining while KPV (a melanocyte-stimulating hormone fragment) calms intestinal inflammation through immune modulation.
The Female Wellness Stack
intermediate — $150-350
Designed specifically for women's health needs. BPC-157 supports gut health and recovery, GHK-Cu targets skin elasticity and collagen production, and PT-141 addresses sexual health and desire through melanocortin receptor activation.
The GLP-1 Recovery Stack
beginner — $300-900
Combines tirzepatide's dual-agonist weight loss power with BPC-157 gut protection. The most common side effects of GLP-1 medications are gastrointestinal. BPC-157 directly addresses nausea, GERD, and gut discomfort during dose escalation.
Explore other goals
Get the Peptide Starter Kit (free)
Quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated April 2026